• Net revenues rose 16% to Rs 150 crore for Q1FY'16 on a YoY basis while EBITDA increased 117% to Rs 26 crore and PAT jumped 113% to Rs 18 crore.

• EBITDA margin of the company improved to 17% in Q1FY'16 from 9% in Q1FY'15 mainly on account of operating leverage

Revenue growth across business units was driven by higher volumes and better realizations

• Refrigerants revenue increased 22% on a YoY basis in Q1FY'16 to Rs 61 crore and 24% on a QoQ basis. Domestic revenues were 59% while exports were 41%.

• Inorganic fluorides revenue decreased 8% on a YoY basis in Q1FY'16 to Rs 24 crore and 4% on a QoQ basis. Domestic revenues were 87% while exports were13%.

• Speciality chemicals revenue increased 22% on a YoY basis in Q1FY'16 to Rs 55 crore but decreased 4% on a QoQ basis. Domestic revenues were 55% while exports were45%.

• CRAMS revenue decreased 8% on a YoY basis in Q1FY'16 to Rs 10 crore but decreased 38% on a QoQ basis. This segment has only export revenues.

• Greenfield Facility at Dahej, Gujarat, a joint venture project at Dahej with Piramal Enterprises to develop, manufacture and sell speciality Fluorochemicals for healthcare segment is expected to come on-stream by H2FY16 with an investments of around Rs.140 crore

• Demand for refrigerant has surged substantially leading to improved realizations. Increasing usage of R22 in pharmaceutical companies and agrochemical companies as feedstock is also augmenting demand. Overseas demand for R22 has remained stable.

• Speciality chemicals continued its good growth in both domestic and overseas market.

• Inorganic chemicals growth was flat during the quarter as this BU was impactedby the weak domestic steel industry. However the company is now targeting exports market

• CRAMS business has performed in line with expectations with clear visibility of the order book supporting its growth

• Capex completed for manufacturing facility for multi ton batch size for CRAMS business unit at Devas at an investment of Rs. 60 crore .New facilities will be India's only plant with high pressure fluorination and cGMP complaint capabilities. Customer audit for the business is under way and it is getting a positive response.

• Benefits of capex at devas would be seen at later part of the year.